MK-6096 is an orally bioavailable potent and selective reversible antagonist of OX(1)R and OX(2)R currently in clinical development for insomnia.

Miquelianin (Quercetin 3-O-glucuronide) is a metabolite of quercetin and a type of natural flavonoid.

Milbemycin oxime is a semi-synthetic macrocyclic lactone prepared by the oxidation and oximation of a mixture of two natural products, milbemycin A3 and A4 (in ~70: 30 ratio). Moxidectin oxime, marketed as Interceptor, is used therapeutically for the prev

MID-1 (ChemBridge5655896) is a specific small molecule MG53-IRS-1 interaction disruptor (MID), but not MG53-FAK and-Cav-3 interaction; increases the IRS-1 protein level in C2C12 myotubes, abrogates MG53-induced IRS-1 ubiquitination and degradation; potent

MHY1485 is mTOR activator that potently inhibits autophagy by suppression of fusion between autophagosomes and lysosomes.

Methyl donor; cofactor for enzyme-catalyzed methylations, including catechol O-methyltransferase (COMT) and DNA methyltransferases (DNMT).

MEK162(ARRY-438162; ARRY-162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM.

Meisoindigo(Natura-α; N-Methylisoindigotin; Dian III), a derivative of Indigo naturalis, might induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML).

Mdivi-1 is a selective cell-permeable inhibitor of mitochondrial division DRP1 (dynamin-related GTPase) and mitochondrial division Dynamin I (Dnm1) with IC50 of 1-10 μM.

MBX-2982 is a selective, orally-available GPR119 agonist for the treatment of type 2 tiabetes.

Marmesin is a coumarin originally isolated from the mature bark of A. marmelos.

Madrasin inhibits pre-mRNA splicing in vitro and modify splicing of endogenous pre-mRNA.

M 344 enhances the sensitivity of human squamous carcinoma cells to radiation and promotes cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells (ED50 = 2.3 μM).

LY364947 is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM, shows 7-fold selectivity over TGFβR-II.

LY2801653 is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM).

LY2801653 2HCl is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM).

LY2795050 is a novel selective κ-opioid Receptor (KOR) antagonist (IC50=0.72 nM) and has the potential as a PET tracer to image KOR in vivo.

LY2608204 is a activator of glucokinase (GK) with EC50 of 42 nM.

LY2334737 is an orally available prodrug of gemcitabine which is a nucleoside analog used as chemotherapy.

LY 3000328 is a potent and selective Cathepsin S (Cat S) inhibitor with IC50s of 7.7 and 1.67 nM for hCat S and mCat S, respectively.

LTI-291 is a Glucocerebrosidase (Gcase) activator for the treament of Parkinson's disease (PD).

Loxiglumide is a Exogenous cholecystokinin (CCK-A) receptor antagonist, stimulates calorie intake and hunger feelings in humans.

Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM, used for lowering cholesterol (hypolipidemic agent).

Losartan carboxylic acid is a physiologically active metabolite of losartan, produced by cytochrome P450 isoforms in the liver.

Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM,showed potent activity against COVID-19(SARS-COV-2).

Lonafarnib(Sch66336) is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B and N-ras with IC50 of 1.9 nM, 5.2 nM and 2.8 nM, respectively.

Lomitapide (AEGR-733) is a novel proprietary MTP-inhibitor.

Lodoxamide tromethamine is a medication for the treatment of prophylaxis of mast cell-mediated allergic disease.

Lodoxamide is an antiallergic compound acting as a mast-cell stabilizer for the treatment of asthma and allergic conjunctivitis.

LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, and can induce TrkB, TrkC, AKT and ERK activation in vitro and in vivo.